Literature DB >> 20124930

Ibudilast inhibits cerebral aneurysms by down-regulating inflammation-related molecules in the vascular wall of rats.

Kenji Yagi1, Yoshiteru Tada, Keiko T Kitazato, Tetsuya Tamura, Junichiro Satomi, Shinji Nagahiro.   

Abstract

OBJECTIVE: Phosphodiesterase-4 (PDE-4) is a cyclic adenosine monophosphate-specific enzyme involved in various inflammatory diseases. We studied its role in and the effect of ibudilast, which predominantly blocks PDE-4, on rat cerebral aneurysms.
METHODS: Cerebral aneurysms were induced at the anterior cerebral artery-olfactory artery bifurcation of female rats subjected to hypertension, increased hemodynamic stress, and estrogen deficiency. The effect of ibudilast (30 or 60 mg/kg/d for 3 months) on their cerebral aneurysms was studied by morphological and immunohistochemical assessment and quantitative real-time polymerase chain reaction assay. In our in vitro study, we grew endothelial cells stimulated by angiotensin II under estrogen-free conditions and examined the effect of ibudilast on PDE-4 activation and the cyclic adenosine monophosphate level.
RESULTS: Morphological evaluation using vascular corrosion casts showed ibudilast significantly suppressed cerebral aneurysms in a dose-dependent manner. In rats with induced cerebral aneurysms, the gene and protein expression of PDE-4 was high, and endothelial leukocyte adhesion molecules (P-selectin, intracellular adhesion molecule 1, and vascular adhesion molecule 1), matrix metalloproteinase-9, and tumor necrosis alpha were expressed. Macrophage migration was also increased. Treatment with ibudilast down-regulated these molecules, suppressed macrophage migration into the aneurysm wall, and inhibited PDE-4 activation and the elevation of cyclic adenosine monophosphate in endothelial cells.
CONCLUSION: These results suggest that blocking of PDE4 is associated with the reduction of inflammation-related molecules and macrophage migration, thereby reducing the progression of cerebral aneurysms. It may represent a new conservative therapy to treat patients with cerebral aneurysms.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20124930     DOI: 10.1227/01.NEU.0000365771.89576.77

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  19 in total

1.  Acute neuroimmune modulation attenuates the development of anxiety-like freezing behavior in an animal model of traumatic brain injury.

Authors:  Krista M Rodgers; Florencia M Bercum; Danielle L McCallum; Jerry W Rudy; Lauren C Frey; Kirk W Johnson; Linda R Watkins; Daniel S Barth
Journal:  J Neurotrauma       Date:  2012-04-26       Impact factor: 5.269

Review 2.  Role of fluid dynamics and inflammation in intracranial aneurysm formation.

Authors:  Alexis S Turjman; Francis Turjman; Elazer R Edelman
Journal:  Circulation       Date:  2014-01-21       Impact factor: 29.690

3.  Site-specific elevation of interleukin-1β and matrix metalloproteinase-9 in the Willis circle by hemodynamic changes is associated with rupture in a novel rat cerebral aneurysm model.

Authors:  Takeshi Miyamoto; David K Kung; Keiko T Kitazato; Kenji Yagi; Kenji Shimada; Yoshiteru Tada; Masaaki Korai; Yoshitaka Kurashiki; Tomoya Kinouchi; Yasuhisa Kanematsu; Junichiro Satomi; Tomoki Hashimoto; Shinji Nagahiro
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

4.  Ibudilast attenuates peripheral inflammatory effects of methamphetamine in patients with methamphetamine use disorder.

Authors:  Michael J Li; Marisa S Briones; Keith G Heinzerling; Mariah M Kalmin; Steven J Shoptaw
Journal:  Drug Alcohol Depend       Date:  2019-11-26       Impact factor: 4.492

Review 5.  Biology of intracranial aneurysms: role of inflammation.

Authors:  Nohra Chalouhi; Muhammad S Ali; Pascal M Jabbour; Stavropoula I Tjoumakaris; L Fernando Gonzalez; Robert H Rosenwasser; Walter J Koch; Aaron S Dumont
Journal:  J Cereb Blood Flow Metab       Date:  2012-07-11       Impact factor: 6.200

6.  Effects of Ibudilast on the Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid Dependence.

Authors:  Verena E Metz; Jermaine D Jones; Jeanne Manubay; Maria A Sullivan; Shanthi Mogali; Andrew Segoshi; Gabriela Madera; Kirk W Johnson; Sandra D Comer
Journal:  Neuropsychopharmacology       Date:  2017-04-10       Impact factor: 7.853

7.  Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.

Authors:  Robert J Fox; Christopher S Coffey; Merit E Cudkowicz; Trevis Gleason; Andrew Goodman; Eric C Klawiter; Kazuko Matsuda; Michelle McGovern; Robin Conwit; Robert Naismith; Akshata Ashokkumar; Robert Bermel; Dixie Ecklund; Maxine Koepp; Jeffrey Long; Sneha Natarajan; Srividya Ramachandran; Thomai Skaramagas; Brenda Thornell; Jon Yankey; Mark Agius; Khurram Bashir; Bruce Cohen; Patricia Coyle; Silvia Delgado; Dana Dewitt; Angela Flores; Barbara Giesser; Myla Goldman; Burk Jubelt; Neil Lava; Sharon Lynch; Augusto Miravalle; Harold Moses; Daniel Ontaneda; Jai Perumal; Michael Racke; Pavle Repovic; Claire Riley; Christopher Severson; Shlomo Shinnar; Valerie Suski; Bianca Weinstock-Gutman; Vijayshree Yadav; Aram Zabeti
Journal:  Contemp Clin Trials       Date:  2016-08-10       Impact factor: 2.226

8.  Interleukin Enhancer Binding Factor 2 Regulates Cell Viability and Apoptosis of Human Brain Vascular Smooth Muscle Cells.

Authors:  Liang Wei; Cheng Yang; Guangxue Wang; Keqin Li; Yanfei Zhang; Hongxin Guan; Zhiyang Sun; Chunlong Zhong
Journal:  J Mol Neurosci       Date:  2020-08-04       Impact factor: 3.444

9.  Inflammation and human cerebral aneurysms: current and future treatment prospects.

Authors:  Joseph S Hudson; Danielle S Hoyne; David M Hasan
Journal:  Future Neurol       Date:  2013-11-01

Review 10.  The development and the use of experimental animal models to study the underlying mechanisms of CA formation.

Authors:  Tomohiro Aoki; Masaki Nishimura
Journal:  J Biomed Biotechnol       Date:  2010-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.